top of page
Medex EU Authorised Representative logo

EU Authorized Representative for Fat Reduction and Body Contouring Equipment: Annex XVI Point 4, Class IIb and the Mandate

Radiofrequency, focused ultrasound, cryolipolysis and laser lipolysis equipment sold for body contouring often has no medical purpose, but point 4 of Annex XVI brings it under the MDR. Commission Implementing Regulation (EU) 2022/2347 makes it class IIb, so a notified body is involved, and a manufacturer outside the EU must designate a sole authorized representative under Article 11(1).

Why fat reduction equipment without a medical purpose falls under the MDR

Radiofrequency, focused ultrasound, cryolipolysis and laser lipolysis equipment sold to beauty salons and clinics for body contouring is often marketed without any medical claim. The MDR applies to it all the same, through Article 1(2) and point 4 of Annex XVI:

"Equipment intended to be used to reduce, remove or destroy adipose tissue, such as equipment for liposuction, lipolysis or lipoplasty."

Source: Regulation (EU) 2017/745, Annex XVI, point 4

The common specifications for this group are set out in Annex V of Commission Implementing Regulation (EU) 2022/2346, which has applied since 22 June 2023:

"This Annex applies to equipment intended to be used to reduce, remove or destroy adipose tissue, such as equipment for liposuction, lipolysis or lipoplasty, listed in Section 4 of Annex XVI to Regulation (EU) 2017/745. This Annex does not apply to active implantable devices."

Source: Commission Implementing Regulation (EU) 2022/2346, Annex V, Section 1

Annex V defines lipolysis as the localised destruction of fat deposit and lipoplasty as the modification of body contours by removal of excess fat. A device whose intended purpose is to reduce, remove or destroy fat is in this group whatever energy it uses. A device used only to tighten skin is not; where it also treats the skin with light, see aesthetic lasers and IPL.

Classification: class IIb

Without a medical purpose, these products would fall to class I under Rule 13. Commission Implementing Regulation (EU) 2022/2347 reclassifies them:

"equipment intended to be used to reduce, remove or destroy adipose tissue as referred to in Section 4 of Annex XVI to Regulation (EU) 2017/745, is reclassified as class IIb;"

Source: Commission Implementing Regulation (EU) 2022/2347, Article 1(b)

ProductClassBasisNotified body
Radiofrequency equipment intended to reduce adipose tissueIIbAnnex XVI point 4; Regulation (EU) 2022/2347, Article 1(b)Yes
Focused ultrasound (HIFU) equipment intended to reduce adipose tissueIIbAnnex XVI point 4; Regulation (EU) 2022/2347, Article 1(b)Yes
Cryolipolysis equipmentIIbAnnex XVI point 4; Regulation (EU) 2022/2347, Article 1(b)Yes
Laser lipolysis equipmentIIbAnnex XVI point 4; Regulation (EU) 2022/2347, Article 1(b)Yes

Class IIb means a notified body is involved before the product is placed on the market. The notified body route is set by Article 52(4) of the MDR.

Transitional provisions and the 1 January 2027 date

Products that were already lawfully on the market in the Union before 22 June 2023 can stay on the market for a limited time while the notified body assessment runs. For a product without a clinical investigation:

"A product for which the manufacturer does not intend to perform a clinical investigation, but in the conformity assessment of which a notified body has to be involved in accordance with Article 52 of that Regulation, may be placed on the market or put into service until 31 December 2028, provided that the following conditions are met: (a) the product was already lawfully marketed in the Union before 22 June 2023 and continues to comply with the requirements of Union and national law that were applicable to it before 22 June 2023; (b) there are no significant changes in the design and intended purpose of the product."

Source: Commission Implementing Regulation (EU) 2022/2346, Article 2(2), as amended by Regulation (EU) 2023/1194

From 1 January 2027 that period comes with a further condition:

"By way of derogation from the first subparagraph, from 1 January 2027 until 31 December 2028, a product that meets the conditions laid down in that subparagraph may only be placed on the market or put into service, if a written agreement for the performance of the conformity assessment has been signed by the notified body and the manufacturer in accordance with Section 4.3, second subparagraph, of Annex VII to Regulation (EU) 2017/745."

Source: Commission Implementing Regulation (EU) 2022/2346, Article 2(2), as amended by Regulation (EU) 2023/1194

For a product that needs a clinical investigation, Article 2(1) of the same Regulation allows placing on the market until 31 December 2029, with a signed notified body agreement required from 1 January 2028. A product first placed on the market on or after 22 June 2023 has no transitional period and needs the notified body certificate first.

The authorized representative: Article 11

Annex XVI products are regulated as devices, so a manufacturer outside the EU needs a sole authorized representative whatever the class:

"Where the manufacturer of a device is not established in a Member State, the device may only be placed on the Union market if the manufacturer designates a sole authorised representative."

Source: Regulation (EU) 2017/745, Article 11(1)

The authorized representative verifies that the declaration of conformity and technical documentation exist and that the notified body procedure has been carried out, keeps copies for competent authorities, registers in EUDAMED and passes complaints and suspected incidents to the manufacturer. Medex is established in Türkiye and registered in EUDAMED under SRN TR-AR-000057550, so one mandate covers the European Union and Türkiye. Placing the product on the Turkish market also requires ÜTS registration, a separate service under a separate contract: see ÜTS registration and market access for Türkiye.

What Medex does under the mandate

We verify the declaration of conformity, the technical documentation and the notified body certificate or the signed notified body agreement for each device, keep copies for the period in Article 10(8), register in EUDAMED, answer competent authority requests and pass complaints and suspected incidents to you without delay. A class IIb device falls in the band of €1,200 to 1,600 per year, fixed for three years from signature; setup is €0 and a change of representative costs nothing. See pricing. We are not a notified body, we do not carry out the clinical evaluation required by the common specifications and we do not find importers or distributors.

The symbol that identifies the representative on your label is explained in our guide to the EC REP meaning. If some devices are still placed on the market under the former directives, see the authorized representative for legacy devices.

Related pages

Other Annex XVI groups: aesthetic lasers and IPL, dermal fillers and contact lenses. All groups are on the medical device categories page. The general guide is EU authorized representative.

Frequently asked questions

Our radiofrequency body contouring device has no medical claim. Does the MDR apply?

Yes, if its intended purpose is to reduce, remove or destroy adipose tissue. Point 4 of Annex XVI covers that equipment, and Regulation (EU) 2022/2346 has applied to it since 22 June 2023.

Which class is cryolipolysis equipment?

Class IIb. Article 1(b) of Regulation (EU) 2022/2347 reclassifies all equipment intended to reduce, remove or destroy adipose tissue as class IIb.

Can we keep selling without a notified body certificate?

Only if the product was lawfully on the market in the Union before 22 June 2023 and has not changed significantly. Without a clinical investigation the period ends on 31 December 2028, and from 1 January 2027 a written agreement with a notified body must be signed.

Does the class change the need for an authorized representative?

No. The need follows from where the manufacturer is established. Article 11(1) applies to every class.

Does one Medex mandate cover the EU and Türkiye?

Yes. Medex is established in Türkiye, and under the EU-Türkiye Customs Union a manufacturer outside both needs one authorized representative, in the EU or in Türkiye.

Sources

Regulation (EU) 2017/745 on medical devices, consolidated text: eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02017R0745-20261109

Commission Implementing Regulation (EU) 2022/2346, consolidated text: eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02022R2346-20230622

Commission Implementing Regulation (EU) 2022/2347: eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32022R2347

bottom of page